Milestone PharmaceuticalsMIST -1.33%26 Market Cap is $155.62 Mil as of Jun. 26, 2026. GuruFocus rates MIST with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 1,431 Biotechnology companies, Milestone Pharmaceuticals ranks better than 54.16% on this metric.
Milestone Pharmaceuticals's quarterly market cap
increased
from Sep. 2025 ($170.34 Mil) to Dec. 2025 ($214.60 Mil) but then
declined
from Dec. 2025 ($214.60 Mil) to Mar. 2026 ($140.17 Mil).
Milestone Pharmaceuticals's annual market cap
increased
from Dec. 2023 ($55.92 Mil) to Dec. 2024 ($125.92 Mil) and
increased
from Dec. 2024 ($125.92 Mil) to Dec. 2025 ($214.60 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Milestone Pharmaceuticals's Enterprise Value for Today is $30.62 Mil.
Milestone Pharmaceuticals (NAS:MIST) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Milestone Pharmaceuticals Market Cap Related Terms
Milestone Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Milestone Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Milestone Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Milestone Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Milestone Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Milestone Pharmaceuticals (MIST) has a Market Cap of $155.62 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Milestone Pharmaceuticals and its competitors. According to the industry distribution chart, Milestone Pharmaceuticals ranks #656 out of 1431 companies in the Biotechnology industry, placing it in the top 45.8%.
Is Milestone Pharmaceuticals' Market Cap too high?
Milestone Pharmaceuticals' current Market Cap is $155.62 Mil. The Biotechnology industry median Market Cap is 113.83. Milestone Pharmaceuticals' value of $155.62 Mil is 36.7% above this industry median. Based on the distribution chart, Milestone Pharmaceuticals ranks #656 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Milestone Pharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Milestone Pharmaceuticals' Market Cap compare to TLSA and DTIL?
According to the Biotechnology industry distribution chart, Milestone Pharmaceuticals ranks #656 out of 1431 companies for Market Cap. This puts Milestone Pharmaceuticals in the upper half of its industry. The industry median Market Cap is 113.83. Milestone Pharmaceuticals' value of $155.62 Mil is 36.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Milestone Pharmaceuticals's current Market Cap of $155.62 Mil is 36.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Milestone Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Milestone Pharmaceuticals's current Market Cap is $155.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Milestone Pharmaceuticals stock overvalued right now?
Milestone Pharmaceuticals (MIST) has a current Market Cap of $155.62 Mil. The current Market Cap is $155.62 Mil and 36.7% above the Biotechnology industry median of 113.83. Milestone Pharmaceuticals' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Milestone Pharmaceuticals (MIST), the current Market Cap is $155.62 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
26GF Score
Get the complete analysis for MIST
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIST has been successfully added to your 
